eprintid: 10125596
rev_number: 13
eprint_status: archive
userid: 608
dir: disk0/10/12/55/96
datestamp: 2021-04-21 14:13:59
lastmod: 2021-04-21 14:13:59
status_changed: 2021-04-21 14:13:59
type: article
metadata_visibility: show
creators_name: Macbeth, F
creators_name: Treasure, T
title: Points to consider regarding the SABR-COMET trial
ispublished: pub
divisions: UCL
divisions: A01
divisions: B04
divisions: C06
divisions: F59
divisions: ZZ4
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
date: 2020-02-14
date_type: published
publisher: ELSEVIER SCIENCE INC
official_url: https://doi.org/10.1016/S0140-6736(19)32494-8
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
article_type: letter
verified: verified_manual
elements_id: 1771189
doi: 10.1016/S0140-6736(19)32494-8
lyricists_name: Treasure, Tom
lyricists_id: TTREA26
actors_name: Treasure, Tom
actors_id: TTREA26
actors_role: owner
full_text_status: public
publication: The Lancet
volume: 395
number: 10222
pagerange: e19
pages: 1
citation:        Macbeth, F;    Treasure, T;      (2020)    Points to consider regarding the SABR-COMET trial.           [Letter].        The Lancet , 395  (10222)   e19.    10.1016/S0140-6736(19)32494-8 <https://doi.org/10.1016/S0140-6736%2819%2932494-8>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10125596/1/Macbeth%20Treasure%20in%20response%20to%20SABR-COMET%20%20200112.pdf